STMicroelectronics N.V. (STMPA)
Euronext Paris · France · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 43.36 |
|---|---|
| 52-week range | 18.20 – 70.85 |
| Return, 1 month / 3 months | −3.9% / −5.3% |
| Return, 1 year / 3 years | +101.2% / +19.1% |
| Trend | Below its 200-day average |
| RSI (14) | 49 |
| Volatility (1 year) | 54.1% |
| Worst drawdown (1 year) | -43.0% |
| Average daily value traded | 99.80M EUR |
| Dividend yield | 0.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
STMicroelectronics is a semiconductor company that designs and makes chips used in electronics. Its products include microcontrollers, power and analog devices, sensors and radio-frequency components. Customers are manufacturers in the automotive, industrial, consumer and communications markets, who use these chips in vehicles, factory equipment, appliances and connected devices. The company is based in Geneva, Switzerland, and has significant operations in France and Italy, where it also runs wafer fabrication and research activities.
STMicroelectronics N.V. trades under the code STMPA on the Euronext Paris in France, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
STMicroelectronics N.V. (STMPA) trades on the Euronext Paris in France. It last closed at EUR 43.36 on 27 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 186 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 101.2% and over the last three months it fell 5.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 60 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -0.3% | ||
| From 52-week high | -37.5% | ||
| Momentum | 76 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -5.3% | ||
| 6-month return | 2.6% | ||
| 12-month return, skipping the last month | 109.3% | ||
| Stability (higher is calmer) | 37 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 54.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -43.0% | ||
| Liquidity | 98 · Strong | Trades actively. | |
| Average daily value traded | 99.80M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 51 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 0.7% | ||
| Years with dividends | 6 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +5.7% |
|---|---|
| 1 month | −3.9% |
| 3 months | −5.3% |
| 6 months | +2.6% |
| 1 year | +101.2% |
| 3 years | +19.1% |
| 5 years | +16.3% |
Signals
| 50-day / 200-day average | 44.22 / 43.51 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.92 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Mar 2027 | EUR 0.0900 |
| 14 Dec 2026 | EUR 0.0900 |
| 21 Sep 2026 | EUR 0.0801 |
| 22 Jun 2026 | EUR 0.0801 |
| 23 Mar 2026 | EUR 0.0801 |
| 15 Dec 2025 | EUR 0.0801 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.